-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the afternoon of September 4, Novarma announced that Novarma Pharmaceuticals Asia Pacific, Middle East and Africa (APMA) President and Novartra China President Yu Xudong had decided to leave Novarma for personal reasons. according to
public information, he holds a bachelor's degree in biology from Peking University, an MBA from Harvard Business School, and a ph.D. in biosciences (cancer research) from Stanford University, and has served as President of AstraZenecom China, Vice President of Marketing and Strategic Planning at AstraZenecom, and Vice President of General Pharmaceuticals.
2011, He left AstraZeneta to join Novarma and was promoted to Head of Novaral Asia Pacific, Middle East and Africa in 2017 as President of Novaral Group (China).
, Yi Xudong has been with Novarce for 10 years.
confirmed Yu Xudong's contribution to Novart's business development in China and Africa.
noted that its achievements included building a customer-facing business organization, driving strong compliance thinking and transforming China's product portfolio.
it is understood that after his departure, Dan Brindle will take over as President of Novart China and Iris Zemzoum will take over as President of the Asia Pacific, Middle East and Africa Region (APMA).
joining Novarma, Iris Zemzoum was Vice President of Strategy for Europe, Middle East and Africa (EMEA) at Janssen, responsible for business strategy, access and medicine.
addition, he spent five years as general manager of Janssen Pharmaceuticals Germany, during which time the company's revenue performance continued to grow by double digits, jumping from 10th to 3rd place.
Iris Zemzoum entered the pharmaceutical industry in 2003, when he joined Shishi Shiguibo.
, she held a number of medical and commercial positions in Germany, Belgium, France and Switzerland, and her responsibilities continued to expand.
joined Novaral, Dan Brindle was a partner at ZY Partners, focusing on corporate law in China and focusing on expanding external strategic partnerships.
, Dan Brindle was Vice President of Asia Pacific and Japanese Government Affairs and Emerging Markets at GlaxoSmithKline, actively promoting the company's business strategy in China and promoting its external relationships.
addition, Dan Brindle has served as Vice President of International Public Affairs and Policy for Asia Pacific at Pfizer and has held a number of key positions at Lilly, including Vice President of Corporate Affairs and Market Access in Emerging Markets and General Manager of Hong Kong and Macau.
said Dan Brindle will work closely together to drive the implementation of China's integration strategy and play an important role in building Novartic's external partnerships and expanding drug access.
, this is not The First Time Novart's first executive change so far this year.
at the beginning of this year, Novarce China also completed the change of old and new presidents, the former GE China Pan-Bohai Region General Manager Yi Wei has officially taken over as China President, the former President Li Zhenfu left for personal reasons.
is understood to have taken over as china's president after 14 years at BP before being GE's general manager in China's Pan Bohai region.
holds a master's degree in industrial economic management from the Graduate School of the Chinese Academy of Social Sciences and a master's degree in business administration from Ashridge School of Management in the United Kingdom, and initially worked in the coordination and negotiation of Sino-foreign joint venture projects in the Office of External Cooperation of Small and Medium-sized Enterprises of the State Planning Commission.
addition to Novaral, the wave of departures from multinational pharmaceutical executives has continued this year.
Such as on August 31, GSK Vice President Wang Hong left for personal reasons, on August 19, Geely's Global Vice President China General Manager Luo Yongqing left in search of external development opportunities, and in August, the head of the specialist medical division of merca East China Hospital also left for external opportunities.
industry analysis pointed out that multinational pharmaceutical companies frequently "departure tide" is actually caused by the domestic pharmaceutical market changes dramatically, the impact of the industry reshuffle intensified.
, especially under the normalization of mining, pharmaceutical companies have to make a series of adjustments for business development, including triggering a major personnel adjustment.